We would love to hear your thoughts about our site and services, please take our survey here.
Anyway answering my own question he knows what he knows so this purchase is definitely positive.
I wonder if this means no RNS on sales this month (as was mentioned by Hardman). Can he buy when he knows price sensitive info is coming?
You should sell out mate, it's obviously stressing you greatly. I think there are some American fund managers who are ready to buy your shares.
Bur surely the front runner would be Viatris.
As per my earlier post they are already committed to paying 30m via their del with STX. They will have provisioned this amount already, so from an accounting perspective the money is spent and can be taken off the price they pay to acquire control.
What would be nice (in my dreams) is a bidding contest between Viatris and Nestle.
Nestle could be a buyer and average down via that route.
Good info Shandy, thanks
BrokeNSmoke
Unfortunately their revenue falling has been running ahead of their costs. Their margins are rubbish, so their costs are too high given their revenue. If they can't grow the revenue (constant downgrading this year) then the need to cut costs which in the business has 2 legs and probably works from home!
Marty has dropped the ball big time over the last 2 years. Time for him to step up and let someone with more operational experience takeover as CEO. Fat chance though...
We have no idea what AOP's average price is but for sure they have been averaging down. I don't believe it will be anywhere near 50p given their take up of shares in the massive dilution since floatation.
I think the best you can do is look at the multiples other business are taken out at and you have examples of this is the last Hardman blurb.
You are right, but thats history. If markets are forward looking the fact that this business trades at this level either means its seriously mis-priced or the market doesn't trust the management to deliver. In this case I think it's both and until Marty sorts out the mess that is the reporting and cost side of the business then SP will struggle.
He should skip Davos this year and concentrate on the numbers.
I fear this is a year away from any substantial improvement.
WPP at 0.8x sales
Publicis 1.2x
SAA 0.6x
SFOR 0.3x
STX usual leaks? Looks like some chunky trades in advance.
Should be dropping in the next few days.
Market cap now less than 1/3rd sales. Incredible....
I am quite suspicious of this type of PR huffing and puffing from fund managers.
If they were strong enough or had enough leverage themselves they could put Foxton's in play. The PR release simply tells me they cant find a buyer and are basically stuck like us PI's, knowing there is value in there but frustrated they cant get it out.
If you were hoping for more you are in the wrong place. This is the place where you look for less....
Looks like Fidelity are the biggest sellers, 13m shares in one qtr!
Yep, why any entrepreneur would want to float on the LSE is beyond me. Well, actually they don't!
Usual jam tomorrow blah blah
"Some early benefits of thiswere evident in 1H’23 and management indicated that this has accelerated in 3Q’23,
such that total Accrufer Rx look set to exceed the number seen for the whole of 1H’23 (in excess of 28,400 compared with 26,284). The full benefits of all this commercial activity are not expected until 4Q’23."
To be released this month according to the Hardman blurb